Aethlon Medical’s stock surged Wednesday, fueled by excitement around a device the company is developing to treat COVID-19 patients by removing the novel coronavirus from their blood. Shares in Aethlon closed Wednesday at $10.79, up 388 percent from Tuesday’s close of $2.21 on the Nasdaq exchange. Trading volume ballooned as well, with nearly 250 million […]

DocWire News with spoke with Mike Clayman, M.D., CEO at Flexion Therapeutics, a company focused on the development of novel, local therapies for the treatment of musculoskeletal conditions – with one approved drug – ZILRETTA® for osteoarthritis knee pain. See what Dr. Clayman had to say about these therapies.

Cartesian President & CEO Murat Kalayoglu, M.D., Ph.D. has led three of his company’s six autoimmune, oncology, and respiratory candidates through Phase I/II clinical trials and two more of them are on the cusp of entering Phase I this year. With so many programs in and entering the clinic, he’s a great choice for a […]